Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Krishnendu Pal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4006-213X; OpenAlex author ID A5076648985. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 13

  1. AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117777↗
  2. Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. Co-author DOI 10.1021/acsabm.5c02077↗
  3. Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in … Co-author DOI 10.1053/j.gastro.2024.09.009↗
  4. Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/pharmaceutics17101334↗
  5. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.mtbio.2024.101199↗
  6. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. First author DOI 10.3390/cancers12051189↗
  7. Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Co-author DOI 10.1016/j.nano.2019.02.020↗
  8. Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic… First author DOI 10.1021/acs.bioconjchem.9b00632↗
  9. Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. First author DOI 10.1039/c9nr05478b↗
  10. Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. Co-author DOI 10.1039/c7nr03172f↗
  11. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.18841↗
  12. Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. Co-author DOI 10.1158/1535-7163.mct-14-0291↗
  13. GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. First author DOI 10.1371/journal.pone.0114409↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Debabrata Mukhopadhyay · 11 shared papers, 2014–2026 · strength 1.59
  2. Hari Krishnareddy Rachamala · 5 shared papers, 2024–2026 · strength 1.32
  3. Naga Malleswara Rao Nakka · 4 shared papers, 2024–2026 · strength 1.01
  4. Santanu Bhattacharya · 5 shared papers, 2014–2026 · strength 0.89
  5. Vijay Sagar Madamsetty · 5 shared papers, 2019–2025 · strength 0.74
  6. Hani M. Babiker · 2 shared papers, 2024–2026 · strength 0.43
  7. Debabrata Mukhopadhyay · 1 shared paper, 2025 · strength 0.30
  8. Tanmay Kulkarni · 1 shared paper, 2026 · strength 0.23
  9. Bengt Fadeel · 2 shared papers, 2019 · strength 0.20
  10. Hsu‐Shan Huang · 1 shared paper, 2019 · strength 0.09
  11. Yun Yen · 1 shared paper, 2019 · strength 0.09
  12. Kabir Mody · 1 shared paper, 2019 · strength 0.09
  13. Mark R Spaller · 2 shared papers, 2014 · strength 0.07
  14. Eduardo N Chini · 1 shared paper, 2017 · strength 0.07
  15. Claudia C.S. Chini · 1 shared paper, 2017 · strength 0.07
  16. Jair Machado Espíndola‐Netto · 1 shared paper, 2017 · strength 0.07
  17. Ruizhi Zhao · 1 shared paper, 2014 · strength 0.04
  18. Suresh T. Chari · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.